LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Crinetics Pharmaceuticals Inc

Cerrado

SectorSalud

34.1 -0.09

Resumen

Variación precio

24h

Actual

Mínimo

33.77

Máximo

35.01

Métricas clave

By Trading Economics

Ingresos

-19M

-116M

Ventas

670K

1M

Margen de beneficio

-11,216.004

Empleados

437

EBITDA

-19M

-129M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+108.48% upside

Dividendos

By Dow Jones

Próximas Ganancias

11 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

537M

3.2B

Apertura anterior

34.19

Cierre anterior

34.1

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

63 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 sept 2025, 23:01 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 sept 2025, 22:48 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 sept 2025, 21:59 UTC

Ganancias

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 sept 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

17 sept 2025, 23:39 UTC

Charlas de Mercado

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 sept 2025, 22:20 UTC

Adquisiciones, fusiones, absorciones

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 sept 2025, 22:19 UTC

Adquisiciones, fusiones, absorciones

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 sept 2025, 22:18 UTC

Adquisiciones, fusiones, absorciones

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 sept 2025, 21:00 UTC

Ganancias

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 sept 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

17 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

17 sept 2025, 19:59 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 19:59 UTC

Charlas de Mercado

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 sept 2025, 19:07 UTC

Charlas de Mercado

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 sept 2025, 18:43 UTC

Charlas de Mercado

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 sept 2025, 18:38 UTC

Charlas de Mercado

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 sept 2025, 18:20 UTC

Charlas de Mercado

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 sept 2025, 18:18 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 18:18 UTC

Charlas de Mercado

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 sept 2025, 18:14 UTC

Charlas de Mercado

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 sept 2025, 17:59 UTC

Charlas de Mercado

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 sept 2025, 17:15 UTC

Adquisiciones, fusiones, absorciones

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 sept 2025, 17:06 UTC

Adquisiciones, fusiones, absorciones

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 sept 2025, 16:51 UTC

Ganancias

Correct: Exor 1H Net Loss -EUR624M

17 sept 2025, 16:34 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 sept 2025, 16:34 UTC

Charlas de Mercado

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 sept 2025, 16:25 UTC

Ganancias

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 sept 2025, 16:23 UTC

Ganancias

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Comparación entre iguales

Cambio de precio

Crinetics Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

108.48% repunte

Estimación a 12 meses

Media 71.09 USD  108.48%

Máximo 97 USD

Mínimo 36 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Crinetics Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

11

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

30.39 / 33.46Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

63 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat